ONCTERNAL THERAPEUTICS INC (ONCT)
US68236P2065 - Common Stock
Taking everything into account, ONCT scores 2 out of 10 in our fundamental rating. ONCT was compared to 571 industry peers in the Biotechnology industry. ONCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ONCT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ONCT has reported negative net income.
ONCT had a negative operating cash flow in the past year.
In the past 5 years ONCT always reported negative net income.
ONCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ONCT has a Return On Assets of -221.62%. This is amonst the worse of the industry: ONCT underperforms 91.36% of its industry peers.
ONCT has a worse Return On Equity (-377.95%) than 77.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| ROIC | N/A |
ROA(3y)-68.44%
ROA(5y)-75.41%
ROE(3y)-79.79%
ROE(5y)-98.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ONCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ONCT has more shares outstanding than it did 1 year ago.
ONCT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -26.49, we must say that ONCT is in the distress zone and has some risk of bankruptcy.
ONCT has a worse Altman-Z score (-26.49) than 89.07% of its industry peers.
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.49 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.39 indicates that ONCT has no problem at all paying its short term obligations.
ONCT has a Current ratio of 2.39. This is in the lower half of the industry: ONCT underperforms 71.96% of its industry peers.
ONCT has a Quick Ratio of 2.39. This indicates that ONCT is financially healthy and has no problem in meeting its short term obligations.
ONCT has a Quick ratio of 2.39. This is in the lower half of the industry: ONCT underperforms 70.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 |
3. Growth
3.1 Past
ONCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.82%, which is quite good.
Looking at the last year, ONCT shows a very strong growth in Revenue. The Revenue has grown by 227.92%.
ONCT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -38.50% yearly.
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.88%
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5YN/A
Sales Q2Q%175.98%
3.2 Future
Based on estimates for the next years, ONCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.92% on average per year.
ONCT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.60% yearly.
EPS Next Y10.27%
EPS Next 2Y10.73%
EPS Next 3Y15.35%
EPS Next 5Y9.92%
Revenue Next Year161.75%
Revenue Next 2Y-2.29%
Revenue Next 3Y16.74%
Revenue Next 5Y3.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ONCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ONCT's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y15.35%
5. Dividend
5.1 Amount
No dividends for ONCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCTERNAL THERAPEUTICS INC
NASDAQ:ONCT (11/22/2024, 8:00:02 PM)
1.14
-0.02 (-1.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.37M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y10.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y